🔗 Share this article

Given that America undertakes sweeping changes to its immunization recommendations, an unexpected name has emerged unexpectedly: Høeg, a US-based physician and epidemiologist who rose to prominence by questioning coronavirus vaccines during the global health crisis and has concentrated on potential fatalities following Covid vaccination in her brief time at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Schedule

Agency leaders were set to unveil radical changes to the pediatric immunization program recently, aligning the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US at odds with many the international standard with insufficient data for benefit. The planned update has been postponed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this year.

Consolidating Power at the FDA

Høeg's temporary position could signify a strengthened alliance between the drug and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon dismantling long-standing vaccines at the FDA.

The new acting director has often pushed for discontinuing some pediatric shot schedules in the US in order to be more similar to the Danish model, a society with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – typically the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Background

Dr. Høeg has little discernible experience in pharmaceutical research, regulation or management, which has been typical for former directors of the biologics center. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a large organization. She has no expertise in industry regulation.”

Former directors of CBER would “grasp legal statutes and the research of drug development”, said a former acting FDA commissioner. “Frankly, she lacks the type of experience that previous people who ran the center have had.”

The drug center has an immense range of responsibilities at the agency, Woodcock pointed out.

“The public just focuses on the new drug program, but the generic drug division approves a multitude of generic drugs. There is also a biosimilars division, OTC medication office and more, and all of those need to be looked after,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial management aspect to the role, which manages over 5,000 employees. “It is a massive management job, if you execute it properly,” she added.

Response and Disputed Programs

Regarding concerns about Høeg’s qualifications and whether this selection indicates greater collaboration among FDA leaders on vaccines, a press secretary responded that the “inquiries are based on inaccurate assumptions”.

“Her experience aligns with the functions of her job,” the representative said, citing the period Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's controversial expedited review system, a contentious rapid drug-approval program that reportedly troubled her predecessors. “By what process are these medications being chosen for this fast-track system? Who takes the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he said, “the agency appears to be shifting towards less stringent rules of all drugs, with the exception of vaccines.”

Established Track Record on Immunizations

Concerning vaccines, Høeg has a clearer, if problematic, history, Howard said. She published a study using unverified crowd-sourced reports to determine the frequency of myocarditis after Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership featured changing guidelines for new vaccines and halting “optional” immunizations, she said following the vote on a audio program. At the FDA, Høeg has according to sources floated the idea of excluding teenage boys from receiving COVID-19 vaccinations.

“She’s an all-around true believer who starts off with her preconceived notions and tailors the evidence to accommodate the data in a very deceptive, untruthful fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined fellow contrarians, {like|